CABALETTA BIO, INC.
Moat Score — Cabaletta Bio, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Cabaletta holds an exclusive worldwide license to IASO's CD19 binder for autoimmune indications plus its own patent families (expected to run 2039-2045) and a broad, published clinical dataset across multiple RESET trials, but as a pre-approval company it has no approved-product IP moat yet. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no commercial-scale manufacturing of its own, Cabaletta has no cost advantage; it relies on external CDMOs (WuXi, Lonza) at costs comparable to or higher than larger, vertically integrated CAR T competitors like Novartis and Gilead. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Cabaletta has no approved product and therefore no current pricing power; any future pricing power would depend entirely on clinical differentiation versus established autoimmune biologics and competing CAR T programs, which cannot be assumed today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy treatment has no network effect; a patient's outcome on rese-cel does not improve because other patients are also treated with it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | A one-time CAR T infusion is inherently a single-use treatment with no repeat-purchase switching dynamic, though if rese-cel proves durable and curative, physicians and patients who see strong results may develop meaningful loyalty to the therapy and its administering centers. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Autoimmune CAR T requires specialized manufacturing and apheresis/treatment center infrastructure that is not trivial to replicate, but numerous well-funded oncology CAR T incumbents (Novartis, Gilead, BMS, J&J/Legend) are entering the same space, undercutting any efficient-scale barrier for a small player like Cabaletta. |